跳至主要内容
临床试验/NCT02806349
NCT02806349已完成2 期

Effect of Co-administration of a Konjac-Glucomannan Fibre Blend and American Ginseng (Panax Quinquefolius L.) on Glycemia and Serum Lipids in Well-controlled Type 2 Diabetes: A Randomized Controlled, Clinical Trial

Vladimir Vuksan2 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2002年3月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
39
试验地点
2
主要终点
HbA1c

研究概览

简要总结

The purpose of this study was to determine whether the co-administration of a konjac-glucomannan fibre blend and American ginseng in a randomized, placebo-controlled, cross-over trial can improve diabetes management.

详细描述

The study used a partially blinded, randomized, placebo controlled, crossover design. Due to the nature of the fibres it was not possible to blind the participant with respect to type of fibre. The study was divided into two phases with each phase having a four 4-week run-in period, and a 12-week treatment period, separated by a minimum 4-week wash-out period.

The treatments consisted of an ad libitum Canadian Diabetes Association recommended diet supplemented with capsules which contained either cornstarch (control) or AG (test) and a fiber supplement consisting of either wheat bran (control) or a viscous fiber blend of konjac mannan and xanthan (test). Participants were asked to attend the clinic at weeks -4, 0, 3, 6, and 12 during each phase.

Outcome measures There were three levels of outcome measures including efficacy, safety, and compliance. Statistical analysis The results are presented as mean ± SEM and considered statistically significant at p<0.05. Statistical analysis was performed using the SAS version 8.2 (SAS Institute, Cary, NC). Parametric analyses were conducted following a comparison of the sampling distribution to a normal distribution (Shapiro-Wilk and Kolmogorov-Smirnov tests). GLM was used to perform two-way ANOVA to detect differences of outcome variables in treatments and visits, controlling for treatment sequence and sex. If the effect of treatment was significant then percent differences were calculated between weeks 12 of test and control and analyzed using the GLM repeated measures one-way ANOVA controlling for sex. Parametric analyses were conducted following a comparison of the sampling distribution to a normal distribution (Shapiro-Wilk and Kolmogorov-Smirnov tests). The tests did not reject the null hypothesis at α=0.05. All comparisons were paired, thus each participant served as his/her own control. As this was a cross-over study, only participants who completed the study were included in the analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of type 2 diabetes of at least 1 year
  • age between 40 and 75 years old
  • treated with diet and anti hyperglycemic medications
  • HbA1c between 6.5% and 8.4%
  • Systolic blood pressure <140mmHg
  • Diastolic blood pressure <90mmHg
  • Clinically euthyroid
  • Normal renal and liver function

排除标准

  • treated with insulin
  • age less than 40 or older than 75 years old at the start of the trial

结局指标

主要结局

HbA1c

时间窗: Week 12

Difference at week 12 between control and test intervention

次要结局

  • Oxidized LDL(Week 12)
  • High sensitivity C reactive protein(Week 12)
  • HDL-cholesterol(week 12)
  • fasting glucose(week 12)
  • Total Cholesterol(Week 12)
  • Apolipoprotein A and B(Week 12)
  • Blood pressure(Week 12)
  • Triglycerides(week 12)
  • fasting insulin(week 12)
  • LDL Cholesterol(week 12)

研究者

发起方
Vladimir Vuksan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Vladimir Vuksan

Senior Scientist

Unity Health Toronto

研究点 (2)

Loading locations...

相似试验